@Home Trading For Sole Propriety

[GotOptions?]

(OTCBB:GTEC) Genesis Equity Partners Acquires Interest in Chinese Pharmaceutical Company

BOCA RATON, Fla., March 21, 2006 (PRIMEZONE) -- Genesis Technology Group, Inc.
(OTCBB:GTEC) announced that its subsidiary, Genesis Equity Partners, LLC, signed
a contract with the Liang Fang Pharmaceuticals, Ltd., one of China's most
respected and innovative drug development, medical device, and retail drug store
enterprises.

Liang Fang reportedly grossed over $15.8 million in revenues, almost $ 2.6
million in net profits in 2005, plus net assets exceeding $ 7.5 million. For the
past three fiscal years combined, Liang Fang's revenues exceeded a total of $
31.2 million. Based on its first quarter sales for 2006, the Beijing-based
manufacturer, which also has 10 retail outlets, forecasts an increase to over
$20 million in revenues this year. Genesis Equity Partners will receive a
significant equity position in Liang Fang and ongoing consulting fees for
coordination and oversight of its U.S. business activities.

Among Liang Fang's best selling products, Valsartan Capsules are a medicine for
primary hypertension or high blood pressure. Valsartan first came to market in
America in 1996, known as Diovan. The Novartis AG version of the Diovan product
generated almost 17 percent of that company's 2004 revenues from branded
pharmaceuticals. Novartis predicted the drug might be its first to generate
annual revenues of more than $5 billion.

Dr. Liu Zhongyi, CEO of Liang Fang, commented: "In July 2001, the National Drug
Administration authorized Liang Fang for the production of Valsartan. With
increased production and marketing, we believe that it should dominate the
Chinese market, where over nine percent of the population suffers from high
blood pressure.

"Valsartan is just one example of the important and successful array of drugs
that Liang Fang has acquired or developed and marketed over the years. Liang
Fang intends to become a global brand, although the market in China is large
enough to sustain our growth rate at over 40% annually. We realize that Western
marketing is often the key to such success, and we intend to capitalize on
Genesis's expertise and network in China, Latin America, and the United States.

"We selected Genesis because of its long history of success and expertise in
China. We carefully studied its GEP merger and acquisition program, and believe
that Liang Fang can flourish globally. In our evaluation, we also reviewed the
performance of another Genesis Chinese client, SunWin Neutraceuticals
(OTCBB:SUWN), and we are confident that Liang Fang could exceed its success, as
a U.S. publicly traded company," concluded Dr. Liu.

Dr. Shaohua Tan, the Genesis Director who negotiated the Liang Fang contract,
added: "We are enthused to add Liang Fang to the list of GEP clients. This
month, Messrs. Wolfson and Clinton joined me in inspecting the world-class Liang
Fang manufacturing plant and two of its Beijing retail stores. The Company's
management, facilities and obvious growth potential impressed us immensely.

"Last month, we announced that Gold Horse International became the newest member
of our innovative merger and acquisition program. Its market sector,
construction and real estate development, ranks among the most active in China.
Now, with Liang Fang, we are entering the health care and pharmaceutical arena,
perhaps the fastest growing industry worldwide."

Annual Shareholders Meeting scheduled on Friday, May 19, 2006, at 1 o'clock P.M.
at the China World Hotel in Beijing, China, located at No. 1 Jianguomenwai
Avenue; telephone [phone], facsimile (8610) 6505-0828, email
[e-mail] and website http://www.shangri-la.com.

About Liang Fang Pharmaceuticals, Limited

Liang Fang Pharmaceuticals, Ltd. is a large comprehensive enterprise which deals
in an integration of the production, trade and retailing of pharmaceuticals. It
possesses the most advanced pharmaceutical-making equipment now in China,
workshops authenticated by the National GMP, a number of first-rate medicines
and other types of medicines produced solely in this corporation, and a large
group of high-tech personnel. Liang Fang covers a business and office area of
2,000 square meters and a storehouse of 1,000 square meters. Altogether there
are four organs attached to this corporation handling respectively the
scientific research on new medicine, the production, wholesale and retail of
medicine.

About Genesis Technology Group, Inc.

Genesis Technology Group, Inc. is a business development firm that fosters
bilateral commerce between Western and Chinese companies. Genesis has created
successful profit centers in product development, manufacturing, distribution,
joint ventures and operational services. The Company has offices in the United
States and China. A 75% owned subsidiary of Genesis, Genesis Equity Capital, LLC
assists Chinese and Western companies in formulating strategies to increase
equity value, while targeting Western stock exchanges as a source of capital and
shareholder support. The core strength of GEP management is creating a first
rate plan to create investor awareness and bring in long-term individual and
institutional investors. GEP should create liquidity in the stock and gain
investor awareness by using tested channels of communications by cogently
articulating the companies' stories. GEP has built successful channels with
expertise in screening and selecting Chinese companies that possess solid
business histories and professional management, and North American public
companies and shells that possess a shareholder base and a history of auditing
and filing, as required by the U.S. Securities & Exchange Commission. For more
information, visit www.genesis-technology.net.

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward-looking
statements." Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future results,
performance or achievements, and may contain the words "estimate," "project,"
"intend," "forecast," "anticipate," "plan," "planning," "expect," "believe,"
"will likely," "should," "could," "would," "may" or words or expressions of
similar meaning. Such statements are not guarantees of future performance and
are subject to risks and uncertainties that could cause the company's actual
results and financial position to differ materially from those included within
the forward-looking statements. Forward-looking statements involve risks and
uncertainties, including those relating to the Company's ability to grow its
business. Actual results may differ materially from the results predicted and
reported results should not be considered as an indication of future
performance. The potential risks and uncertainties include, among others, the
Company's limited operating history, the limited financial resources, domestic
or global economic conditions -- especially those relating to China, activities
of competitors and the presence of new or additional competition, and changes in
Federal or State laws, restrictions and regulations on doing business in a
foreign country, in particular China, and conditions of equity markets. More
information about the potential factors that could affect the Company's business
and financial results is included in the Company's filings, available via the
United States Securities and Exchange Commission.

-0-
CONTACT: Genesis Technology Group, Inc.
Kenneth Clinton
[phone]

21Mar06 11:30 GMT
Symbols:
us;GTEC
Source PZM PrimeZone Media
Categories:
MST/R/G7 MST/R/NME MST/R/US TGT/BGN